Study Investigates Inherent Contamination in Deep Well Microplates
News Oct 21, 2014
A recent study by the Department of Chemistry at the University of Kent, UK provides a detailed analysis of deep well microplates and the significant levels of contamination found in more than 50% of the commercially available plates tested.
The study, following on from an earlier study in 2005, gives data on a large range of microplates from numerous manufacturers based in Europe, USA and China. Mass spectral data shows that persistent contamination from a range of compounds found in the raw polymer master batch continues to be evident in many of the microplates tested.
The effect of extractables leached out of the deep well plates identified in this report depends on the exact application for which the plate was designed but is highly likely to significantly affect their performance and contaminate samples stored in them.
The authors of the report conclude it is likely that a low grade polypropylene was used in the production of many of the microplates that leached extractables when tested. Such low grade polypropylene often contains flow modifier additives or “mould release agents” which will have been used to ease the manufacturing process and help free the moulded microplate from the mould respectively.
The solvent used for "extraction" of potential leachates in this study was methanol. As mass spectral testing was undertaken after only 24 hours, it is clear that samples do not have to be in these plates for very long before they can become contaminated.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE